Health Blueprint

Back to Longevity News

News summary

IASO Bio Hosts FUCASO Singapore Launch Event, Marking the Official Commercial Landing of China

Source: PR Newswire • Published: 04 Nov 2026, 04:59

Summarized by Masters of Longevity from PR Newswire.

Singapore approved and commercially launched FUCASO for adult R/R multiple myeloma patients.

IASO Bio Hosts FUCASO Singapore Launch Event, Marking the Official Commercial Landing of China
Key Takeaways
  • FUCASO was approved and launched in Singapore for R/R MM.
  • IASO Bio validated a China-to-Singapore cross-border manufacturing model.
  • Pivotal trial showed very high response rates and long PFS.
Read the full article at PR Newswire ↗

Continue exploring

Recommended MoL Picks

MoL PickApple Brings Longevity to the Wrist. What Will It Change?Apple’s new Health Age, readiness and movement tools bring long-term health into everyday view. The opportunity is turning that information into useful action.MoL PickSeed Oils and Health: Inflammation, Processing and EvidenceHuman trials, processing risks and long-term health ask different questions. What can seed-oil research tell us—and what remains unresolved?MoL PickBiotin for Hair Growth: The Weak Evidence—and the Blood-Test Risk Most People MissBiotin deficiency can affect hair. That does not mean more biotin makes healthy hair grow—and high doses can distort important laboratory results.